Predictive Oncology Inc.
Predictive Oncology Inc. Fundamental Analysis
Predictive Oncology Inc. (POAI) shows moderate financial fundamentals with a PE ratio of -0.31, profit margin of -1860.53%, and ROE of 29.59%. The company generates $0.0B in annual revenue with weak year-over-year growth of -8.78%.
Key Strengths
Areas of Concern
The stock receives a Fundamental Health Score of -139500.0/100 based on profitability, valuation, growth, and balance sheet metrics. The F grade reflects weak fundamentals and significant financial concerns.
Fundamental Health Score
We analyze POAI's fundamental strength across five key dimensions:
Efficiency Score
WeakPOAI struggles to generate sufficient returns from assets.
Valuation Score
ExcellentPOAI trades at attractive valuation levels.
Growth Score
ModeratePOAI shows steady but slowing expansion.
Financial Health Score
ExcellentPOAI maintains a strong and stable balance sheet.
Profitability Score
WeakPOAI struggles to sustain strong margins.
Key Financial Metrics
Is POAI Expensive or Cheap?
P/E Ratio
POAI trades at -0.31 times earnings. This suggests potential undervaluation.
PEG Ratio
When adjusting for growth, POAI's PEG of -0.00 indicates potential undervaluation.
Price to Book
The market values Predictive Oncology Inc. at 1.50 times its book value. This may indicate undervaluation.
EV/EBITDA
Enterprise value stands at -0.05 times EBITDA. This is generally considered low.
How Well Does POAI Make Money?
Net Profit Margin
For every $100 in sales, Predictive Oncology Inc. keeps $-1860.53 as profit after all expenses.
Operating Margin
Core operations generate -1858.61 in profit for every $100 in revenue, before interest and taxes.
ROE
Management delivers $29.59 in profit for every $100 of shareholder equity.
ROA
Predictive Oncology Inc. generates $-4.41 in profit for every $100 in assets, demonstrating efficient asset deployment.
Following the Money - Real Cash Generation
Operating Cash Flow
Predictive Oncology Inc. generates limited operating cash flow of $-394.70K, signaling weaker underlying cash strength.
Free Cash Flow
Predictive Oncology Inc. generates weak or negative free cash flow of $-394.70K, restricting financial flexibility.
FCF Per Share
Each share generates $-0.54 in free cash annually.
FCF Yield
POAI converts -3.18% of its market value into free cash.
Financial Ratios Analysis
Valuation Ratios
P/E Ratio
Price to earnings ratio
-0.31
vs 25 benchmark
PEG Ratio
Price/earnings to growth ratio
-0.00
vs 25 benchmark
P/B Ratio
Price to book value ratio
1.50
vs 25 benchmark
P/S Ratio
Price to sales ratio
23.76
vs 25 benchmark
Financial Health
Debt/Equity
Total debt to shareholders' equity
0.03
vs 25 benchmark
Current Ratio
Current assets to current liabilities
10.02
vs 25 benchmark
Efficiency Ratios
ROE
Return on equity percentage
29.59
vs 25 benchmark
ROA
Return on assets percentage
-4.41
vs 25 benchmark
ROCE
Return on capital employed
-4.79
vs 25 benchmark
How POAI Stacks Against Its Sector Peers
| Metric | POAI Value | Sector Average | Performance |
|---|---|---|---|
| P/E Ratio | -0.31 | 28.45 | Better (Cheaper) |
| ROE | 2958.98% | 763.00% | Excellent |
| Net Margin | -186053.45% | -45265.00% (disorted) | Weak |
| Debt/Equity | 0.03 | 0.34 | Strong (Low Leverage) |
| Current Ratio | 10.02 | 2795.60 | Strong Liquidity |
| ROA | -440.73% | -16588.00% (disorted) | Weak |
POAI outperforms its industry in 4 out of 6 key metrics, particularly excelling in ROE, but lagging in Net Margin.
Historical Growth Performance
5-Year Growth Trajectory
This section reviews Predictive Oncology Inc.'s 5-year compound annual growth rate (CAGR) and compares its performance against the typical investment style of its industry.
Revenue CAGR
-97.02%
Industry Style: Defensive, Growth, Innovation
DecliningEPS CAGR
98.37%
Industry Style: Defensive, Growth, Innovation
High GrowthFCF CAGR
96.74%
Industry Style: Defensive, Growth, Innovation
High Growth